O
OliX Pharmaceuticals Inc
KOSDAQ:226950
OliX Pharmaceuticals Inc
KOSDAQ:226950
Price:
203 000
KRW
-1.93%
Market Closed
Market Cap:
₩4.1T
Balance Sheet
Balance Sheet Decomposition
OliX Pharmaceuticals Inc
OliX Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
OliX Pharmaceuticals Inc
OliX Pharmaceuticals Inc
Balance Sheet
OliX Pharmaceuticals Inc
OliX Pharmaceuticals Inc
Currency: KRW
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
629
|
678
|
2 813
|
4 954
|
11 329
|
34 337
|
4 930
|
9
|
3 883
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3 892
|
|
| Cash Equivalents |
629
|
678
|
2 813
|
4 954
|
11 329
|
34 337
|
4 930
|
9
|
8
|
|
| Short-Term Investments |
8 855
|
14 181
|
44 244
|
30 586
|
56 782
|
15 421
|
56 941
|
13 942
|
8 531
|
|
| Total Receivables |
170
|
244
|
287
|
541
|
518
|
552
|
1 147
|
5 283
|
1 082
|
|
| Accounts Receivables |
57
|
55
|
185
|
68
|
44
|
92
|
827
|
3 635
|
1 003
|
|
| Other Receivables |
113
|
189
|
102
|
473
|
474
|
459
|
321
|
1 648
|
79
|
|
| Inventory |
0
|
730
|
635
|
366
|
304
|
374
|
657
|
468
|
554
|
|
| Other Current Assets |
431
|
341
|
719
|
992
|
114
|
1 556
|
1 369
|
466
|
1 484
|
|
| Total Current Assets |
10 084
|
16 174
|
48 698
|
37 440
|
69 047
|
52 240
|
65 046
|
32 142
|
15 534
|
|
| PP&E Net |
4 767
|
5 136
|
5 221
|
5 911
|
6 180
|
31 525
|
37 232
|
43 910
|
51 385
|
|
| PP&E Gross |
4 767
|
5 136
|
5 221
|
5 911
|
6 180
|
31 525
|
37 232
|
43 910
|
51 385
|
|
| Accumulated Depreciation |
161
|
417
|
833
|
1 428
|
2 292
|
3 664
|
4 699
|
6 363
|
6 856
|
|
| Intangible Assets |
228
|
298
|
1 339
|
1 411
|
2 529
|
2 134
|
2 107
|
1 981
|
1 705
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
1
|
26 809
|
23 481
|
1 986
|
|
| Other Long-Term Assets |
70
|
32
|
379
|
446
|
821
|
772
|
1 458
|
1 312
|
640
|
|
| Total Assets |
15 149
N/A
|
21 640
+43%
|
55 637
+157%
|
45 207
-19%
|
78 577
+74%
|
86 672
+10%
|
132 651
+53%
|
102 825
-22%
|
71 249
-31%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accrued Liabilities |
0
|
12
|
16
|
25
|
80
|
298
|
359
|
465
|
489
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
340
|
0
|
0
|
16
|
259
|
16 893
|
20 289
|
1 065
|
17 759
|
|
| Other Current Liabilities |
491
|
1 021
|
299
|
2 714
|
4 150
|
23 174
|
18 895
|
5 033
|
11 813
|
|
| Total Current Liabilities |
832
|
1 033
|
314
|
2 754
|
4 488
|
40 365
|
39 543
|
6 563
|
30 060
|
|
| Long-Term Debt |
1 400
|
1 400
|
0
|
207
|
14 268
|
20 378
|
23 826
|
38 292
|
21 434
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
1 647
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
9
|
65
|
886
|
295
|
481
|
624
|
|
| Other Liabilities |
360
|
531
|
385
|
439
|
12 823
|
6 522
|
3 080
|
7 634
|
1 282
|
|
| Total Liabilities |
2 592
N/A
|
2 964
+14%
|
699
-76%
|
3 409
+388%
|
33 292
+877%
|
68 151
+105%
|
66 744
-2%
|
52 971
-21%
|
53 400
+1%
|
|
| Equity | ||||||||||
| Common Stock |
2 263
|
2 603
|
3 252
|
3 265
|
6 771
|
6 852
|
8 352
|
8 447
|
9 230
|
|
| Retained Earnings |
7 152
|
12 316
|
20 058
|
34 411
|
53 796
|
83 511
|
103 006
|
122 108
|
162 767
|
|
| Additional Paid In Capital |
17 446
|
28 402
|
71 953
|
73 217
|
92 922
|
92 908
|
151 895
|
157 177
|
175 533
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
4 215
|
1 427
|
9 991
|
|
| Other Equity |
0
|
12
|
209
|
273
|
611
|
2 272
|
4 453
|
4 912
|
5 844
|
|
| Total Equity |
12 557
N/A
|
18 676
+49%
|
54 938
+194%
|
41 798
-24%
|
45 286
+8%
|
18 521
-59%
|
65 907
+256%
|
49 855
-24%
|
17 849
-64%
|
|
| Total Liabilities & Equity |
15 149
N/A
|
21 640
+43%
|
55 637
+157%
|
45 207
-19%
|
78 577
+74%
|
86 672
+10%
|
132 651
+53%
|
102 825
-22%
|
71 249
-31%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
9
|
10
|
13
|
13
|
14
|
14
|
14
|
16
|
18
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
1
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
